The aim of this project is to evaluate the use and adequacy of chemotherapy in patients with advanced cancer, as well as trying to reduce it significantly. This studio
is financed through the Carlos III Health Institute (PI18 / 00034, PFIS FI19 / 00335) and co-financed by
the European Regional Development Fund.